VIS Quiz Question #4

Make It Routine: Screening for Cognitive Decline in Primary Care

Your daily dose of the clinical news you may have missed.

Anna Chodos, MD, MPH;Sydney Jennings

July 24th 2025

FDA Mandates Major Changes to Opioid Labeling

Listen to our latest podcast episode to discover how early dementia detection enhances care and quality of life, with actionable strategies for primary care teams to implement now.

The Weekly Dose: Insights on Atopic Dermatitis, Menopause Care, Cancer Screening, and Weight Loss Therapy

The FDA requires all manufacturers of opioid pain medications to revise labeling to emphasize and explain risks with long-term use.

July 23rd 2025

FDA Label Update Positions Inclisiran as First-Line Monotherapy for Hypercholesterolemia

Insights on an FDA-approved multi-cancer detection test, the impact of obesity pharmacotherapy adherence on weight loss outcomes, and more.

Lecanemab Shows Sustained Benefit at 4 Years in Early Alzheimer Disease: AAIC 2025

Inclisiran can now be used without a background statin, as an adjunct to changes in diet and physical activity for reduction of LDL-C in hypercholesterolemia.

New Guidelines Recommend Preconception Screening in Diabetes: Daily Dose

Four-year data show lecanemab slows clinical decline in early Alzheimer disease and maintains a consistent safety profile.

Related Content

Make It Routine: Screening for Cognitive Decline in Primary Care

Your daily dose of the clinical news you may have missed.

Anna Chodos, MD, MPH;Sydney Jennings

July 24th 2025

FDA Mandates Major Changes to Opioid Labeling

Listen to our latest podcast episode to discover how early dementia detection enhances care and quality of life, with actionable strategies for primary care teams to implement now.

The Weekly Dose: Insights on Atopic Dermatitis, Menopause Care, Cancer Screening, and Weight Loss Therapy

The FDA requires all manufacturers of opioid pain medications to revise labeling to emphasize and explain risks with long-term use.

July 23rd 2025

FDA Label Update Positions Inclisiran as First-Line Monotherapy for Hypercholesterolemia

Insights on an FDA-approved multi-cancer detection test, the impact of obesity pharmacotherapy adherence on weight loss outcomes, and more.

Lecanemab Shows Sustained Benefit at 4 Years in Early Alzheimer Disease: AAIC 2025

Inclisiran can now be used without a background statin, as an adjunct to changes in diet and physical activity for reduction of LDL-C in hypercholesterolemia.